ADAMS EXPRESS CO Form N-CSRS July 28, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number: 811-00248

THE ADAMS EXPRESS COMPANY

-----

(Exact name of registrant as specified in charter)

7 Saint Paul Street, Suite 1140, Baltimore, Maryland 21202

(Address of principal executive offices) (Zip code)

Lawrence L. Hooper, Jr.
The Adams Express Company
7 Saint Paul Street
Suite 1140
Baltimore, Maryland 21202

Registrant's telephone number, including area code: 410-752-5900

Date of fiscal year end: December 31, 2005

Date of reporting period: June 30, 2005

Item 1: Reports to Stockholders.

#### THE ADAMS EXPRESS COMPANY

\_\_\_\_\_\_

### Board of Directors

Enrique R. Arzac/ 1,3/ Kathleen T. McGahran /2,4/
Phyllis O. Bonanno /1,3/ Douglas G. Ober/ 1/
Daniel E. Emerson/ 3,4 / John J. Roberts/ 1,4 /
Thomas H. Lenagh/ 1,4/ Susan C. Schwab/ 2,4 /
W.D. MacCallan/ 2,3/ Robert J.M. Wilson/ 1,2 /

- 1. Member of Executive Committee
- 2. Member of Audit Committee
- 3. Member of Compensation Committee
- 4. Member of Retirement Benefits Committee

Officers

Douglas G. Ober Chairman and

Chief Executive Officer

Joseph M. Truta President

Lawrence L. Hooper, Jr. Vice President, General

Counsel and Secretary

Maureen A. Jones Vice President,

Chief Financial Officer

and Treasurer

Stephen E. Kohler

David R. Schiminger

D. Cotton Swindell

Christine M. Sloan

Geraldine H. Pare

Vice President--Research

Vice President--Research

Assistant Treasurer

Assistant Secretary

Stock Data

Market Price (6/30/05) \$12.87 Net Asset Value (6/30/05) \$15.06 Discount: 14.5%

New York Stock Exchange and Pacific Exchange ticker symbol: ADX NASDAQ Mutual Fund Quotation Symbol: XADEX Newspaper stock listings are generally under the abbreviation: AdaEx

Distributions in 2005

From Investment Income (paid or declared) \$0.14
From Net Realized Gains 0.01
---Total \$0.15

2005 Dividend Payment Dates

March 1, 2005 June 1, 2005 September 1, 2005 December 27, 2005\*

\*Anticipated

Semi-Annual Report June 30,2005

[GRAPHIC]

[GRAPHIC]

#### LETTER TO STOCKHOLDERS

\_\_\_\_\_

We submit herewith the audited financial statements of the Company for the six months ended June 30, 2005. Also provided are the report of the independent registered public accounting firm, a schedule of investments and other summary financial information.

Net assets of the Company at June 30, 2005 were \$15.06 per share on 84,960,583 shares outstanding, compared with \$15.04 per share at December 31, 2004 on 86,135,292 shares outstanding. On March 1, 2005, a distribution of \$0.05 per share was paid, consisting of \$0.03 from 2004 investment income, \$0.01 from 2004 short-term capital gain, and \$0.01 from 2005 investment income, all taxable in 2005. A 2005 investment income dividend of \$0.05 per share was paid on June 1, 2005 and another \$0.05 investment income dividend has been declared to shareholders of record August 16, 2005, payable on September 1, 2005.

Net investment income for the six months ended June 30, 2005 amounted to \$8,701,535, compared with \$7,719,995 for the same period in 2004. These earnings are equal to \$0.10 and \$0.09 per share, respectively, on the average number of shares outstanding during each period.

Net capital gain realized on investments for the six months ended June 30, 2005 amounted to \$17,716,584, the equivalent of \$0.21 per share.

The Annual Meeting, held on April 27, 2005 in Baltimore, was well attended. The results of the voting at the Annual Meeting are shown on page 17.

Current and potential shareholders can find information about the Company, including the daily net asset value (NAV) per share, the market price, and the discount/ premium to the NAV, at its website (www.adamsexpress.com). Also available at the website are a history of the Company, historical financial information, and other useful information. Further information regarding shareholder services is located on page 18 of this report.

Mr. W. Perry Neff retired from the Board of Directors in April 2005. Mr. Neff was elected to the Board in 1987 and generously shared his extensive financial knowledge acquired from his long and successful career in the banking industry. We wish him well in his retirement and thank him for his eighteen years of distinguished service as a director.

We are pleased to announce effective April 27, 2005, the Board of Directors elected Mr. David R. Schiminger to Vice President--Research. Mr. Schiminger has been with the Company since 2002 as a research analyst covering the healthcare and consumer staples sectors.

-----

The Company is an internally-managed equity fund whose investment policy is based on the primary objectives of preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation.

By order of the Board of Directors, /s/ DOUGLAS G. OBER Douglas G. Ober, Chairman and Chief Executive Officer /s/ JOSEPH M. TRUTA

Joseph M. Truta, President

July 20, 2005

### STATEMENT OF ASSETS AND LIABILITIES

\_\_\_\_\_\_

June 30, 2005

Cash Receivables: Investment securities sold Dividends and interest Investment securities sold Dividends and interest Investment securities sold Prepaid pension cost Investment securities sold Investment securities sold Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Investment securities purchased Invest	Assets Investments* at value:    Common stocks and convertible securities    (cost \$890,690,578) Non-controlled affiliate, Petroleum & Resources Corporation    (cost \$27,963,162)	\$1,184,235,477 59,579,880
Receivables: Investment securities sold Dividends and interest Prepaid pension cost S, Prepaid expenses and other assets Investment securities purchaset  Liabilities Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses Accrued expenses Accrued expenses Accrued expenses S, Total Liabilities A, Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) S, Additional capital surplus Undistributed net investment income Undistributed net realized gain on investments S, Unrealized appreciation on investments S24, Net Assets Applicable to Common Stock \$1,279,	Short-term investments (cost \$30,767,784)	30,767,784 \$1,274,5
Prepaid expenses and other assets  1, 283,  Liabilities Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses  3,  Total Liabilities  4,  Net Assets  Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6)  \$ 84, Additional capital surplus Undistributed net investment income  \$ 5, Undistributed net realized gain on investments  Unrealized appreciation on investments  \$ 18,  Net Assets Applicable to Common Stock  \$ \$1,279,	Receivables: Investment securities sold Dividends and interest	2 1,4
Total Assets 1,283,  Liabilities Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses 3,  Total Liabilities 4,  Net Assets \$1,279,  Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) \$84, Additional capital surplus 845, Undistributed net investment income 5,  Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		5,5 1,5
Liabilities Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses 3,  Total Liabilities 4,  Net Assets \$1,279,  Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) \$ 84, Additional capital surplus 845, Undistributed net investment income 5, Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		
Investment securities purchased Open written option contracts at value (proceeds \$765,056) Accrued expenses 3,  Total Liabilities 4,  Net Assets \$1,279,  Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) \$ 84, Additional capital surplus 845, Undistributed net investment income 5, Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		
Open written option contracts at value (proceeds \$765,056)  Accrued expenses 3,  Total Liabilities 4,  Net Assets \$1,279,  Net Assets  Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) \$ 84, Additional capital surplus 845, Undistributed net investment income 5, Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		2
Net Assets  Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6)  \$ 84, Additional capital surplus Undistributed net investment income  Undistributed net realized gain on investments  18, Unrealized appreciation on investments  Net Assets Applicable to Common Stock  \$ 1,279,	Open written option contracts at value (proceeds \$765,056)	9 3 <b>,</b> 0
Net Assets  Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6)  Additional capital surplus Undistributed net investment income Undistributed net realized gain on investments  Net Assets Applicable to Common Stock  \$1,279,		4,2
Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares; issued and outstanding 84,960,583 shares (includes 13,941 restricted shares and restricted stock units for 6,750 shares) (Note 6) \$ 84, Additional capital surplus Undistributed net investment income Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324, Net Assets Applicable to Common Stock \$1,279,	Net Assets	\$1,279,2
shares and restricted stock units for 6,750 shares) (Note 6)  Additional capital surplus  Undistributed net investment income  Undistributed net realized gain on investments  Unrealized appreciation on investments  Net Assets Applicable to Common Stock  \$1,279,	Net Assets Common Stock at par value \$1.00 per share, authorized 150,000,000 shares;	
Undistributed net investment income 5, Undistributed net realized gain on investments 18, Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		,-
Undistributed net realized gain on investments  Unrealized appreciation on investments  Net Assets Applicable to Common Stock  \$1,279,	* *	845,3
Unrealized appreciation on investments 324,  Net Assets Applicable to Common Stock \$1,279,		5 <b>,</b> 8
Net Assets Applicable to Common Stock \$1,279,		324,9
	Net Assets Applicable to Common Stock	\$1,279,2
Net Asset Value Per Share of Common Stock	Net Asset Value Per Share of Common Stock	

<sup>\*</sup>See Schedule of Investments on pages 9 through 10.

The accompanying notes are an integral part of the financial statements.

### STATEMENT OF OPERATIONS

\_\_\_\_\_\_

### Six Months Ended June 30, 2005

<pre>Investment Income Income:    Dividends:</pre>	
	\$ 10,7
From non-controlled affiliate	3
Interest and other income	3
Total Income	11,4
Expenses:	
Investment research	1,2
Administration and operations	5
Directors' fees	11
Reports and stockholder communications	1
Transfer agent, registrar and custodian expenses	Щ
Auditing and accounting services Legal services	1
Occupancy and other office expenses	<del>'</del>
Travel, telephone and postage	2
Other	
Total Expenses	2,7
Net Investment Income	8,7
Realized Gain and Change in Unrealized Appreciation on Investments	
Net realized gain on security transactions	17,5
Net realized gain distributed by regulated investment company (non-controlled affiliate)	1
Change in unrealized appreciation on investments	(18,6
Net Gain(Loss) on Investments	(9
Change in Net Assets Resulting from Operations	\$ 7,7

The accompanying notes are an integral part of the financial statements.

3

STATEMENTS OF CHANGES IN NET ASSETS

\_\_\_\_\_\_

	Six Months Ended June 30, 2005	December 31, 2004
From Operations: Net investment income		\$ 19,008,405
Net realized gain on investments Change in unrealized appreciation on investments	·	54,713,903 61,557,921
Change in net assets resulting from operations	7,727,630	135,280,229
Distributions to Stockholders from: Net investment income Net realized gain from investment transactions		(20,157,724) (55,099,990)
Decrease in net assets from distributions	(8,545,932)	(75,257,714)
From Capital Share Transactions:  Value of shares issued in payment of distributions  Cost of shares purchased (Note 4)  Deferred compensation (Notes 4, 6)	 (15,489,364) 23,858	35,690,590 (19,026,661)
Change in net assets from capital share transactions	(15, 465, 506)	16,663,929
Total Change in Net Assets	(16,283,808)	76,686,444
Net Assets: Beginning of period	1,295,548,900	1,218,862,456
End of period (including undistributed net investment income of \$5,814,847 and \$5,038,545, respectively)	\$1,279,265,092	\$1,295,548,900

The accompanying notes are an integral part of the financial statements.

4

### NOTES TO FINANCIAL STATEMENTS

------

### 1. Significant Accounting Policies

The Adams Express Company (the Company) is registered under the Investment Company Act of 1940 as a diversified investment company. The Company's investment objectives as well as the nature and risk of its investment transactions are set forth in the Company's registration statement.

Security Valuation -- Investments in securities traded on a national security exchange are valued at the last reported sale price on the day of valuation. Over-the-counter and listed securities for which a sale price is not available are valued at the last quoted bid price. Short-term investments (excluding purchased options) are valued at amortized cost. Purchased and written options are valued at the last quoted asked price.

Affiliated Companies -- Investments in companies 5% or more of whose

outstanding voting securities are held by the Company are defined as "Affiliated Companies" in Section 2(a)(3) of the Investment Company Act of 1940.

Security Transactions and Investment Income -- Investment transactions are accounted for on the trade date. Gain or loss on sales of securities and options is determined on the basis of identified cost. Dividend income and distributions to shareholders are recognized on the ex-dividend date, and interest income is recognized on the accrual basis.

### 2. Federal Income Taxes

The Company's policy is to distribute all of its taxable income to its shareholders in compliance with the requirements of the Internal Revenue Code applicable to regulated investment companies. Therefore, no federal income tax provision is required. For federal income tax purposes, the identified cost of securities at June 30, 2005 was \$948,934,273 and net unrealized appreciation aggregated \$325,648,868, of which the related gross unrealized appreciation and depreciation were \$432,136,900 and \$106,488,032, respectively.

Distributions are determined in accordance with income tax regulations which may differ from generally accepted accounting principles. Accordingly, annual reclassifications are made within the Company's capital accounts to reflect income and gains available for distribution under income tax regulations.

### 3. Investment Transactions

The Company's investment decisions are made by a committee of management, and recommendations to that committee are made by the research staff.

Purchases and sales of portfolio securities, other than options and short-term investments, during the six months ended June 30, 2005 were \$91,383,757 and \$102,728,044, respectively. Options may be written (sold) or purchased by the Company. The Company, as writer of an option, bears the risks of possible illiquidity of the option markets and from movements in security values. The risk associated with purchasing an option is limited to the premium originally paid. A schedule of outstanding option contracts as of June 30, 2005 can be found on page 12.

Transactions in written covered call and collateralized put options during the six months ended June 30, 2005 were as follows:

	Covered Calls		Collateralized Put	
- ( -	Contracts	Premiums	Contracts	Premiums
ions outstanding,				
cember 31, 2004	3,600	\$ 386,349	2,655	\$ 268,082
ions written	6,430	721,641	4,140	475,563
ions terminated in closing				
rchase transactions	(936)	(98,506)		
ions expired	(3,034)	(339,834)	(3,485)	(361,698)
ions exercised	(1,780)	(207,743)	(650)	(78,798)
ions outstanding,				
ne 30, 2005	4,280	\$ 461,907	2,660	\$ 303,149
ions written ions terminated in closing rchase transactions ions expired ions exercised ions outstanding,	(936) (3,034) (1,780)	721,641 (98,506) (339,834) (207,743)	4,140  (3,485) (650)	475, (361, (78,

### 4. Capital Stock

The Company has 10,000,000 authorized and unissued preferred shares without par value.

On December 27, 2004, the Company issued 2,745,430 shares of its Common Stock at a price of \$13.00 per share (the average market price on December 13, 2004) to stockholders of record on November 23, 2004 who elected to take stock in payment of the year-end distribution from 2004 capital gain and investment income.

The Company may purchase shares of its Common Stock from time to time at such prices and amounts as the Board of Directors may deem advisable.

Transactions in Common Stock for 2005 and 2004 were as follows:

	Sh	ares	Amo	unt 
	June 30,	Year ended December 31,	Six months ended June 30, 2005	December 31,
Shares issued in payment of dividends Shares purchased (at a weighted average discount		2,745,430	\$	\$ 35,690,590
from net asset value of 12.6% and 13.0%, respectively) Nonvested shares/units granted under the	(1,195,400)	(1,496,550)	(15,489,364)	(19,026,661)
Equity Incentive Compensation Plan	20,691		23,858	
Net change	(1,174,709)	1,248,880	\$(15,465,506)	\$ 16,663,929

### 5. Retirement Plans

The Company's qualified defined benefit pension plan covers all employees with at least one year of service. In addition, the Company has a nonqualified defined benefit plan which provides eligible employees with retirement benefits to supplement the qualified plan. Benefits are based on length of service

5

#### NOTES TO FINANCIAL STATEMENTS (CONTINUED)

\_\_\_\_\_\_

and compensation during the last five years of employment. The Company's policy is to contribute annually to the plans those amounts that can be deducted for federal income tax purposes, plus additional amounts as the Company deems

appropriate in order to provide assets sufficient to meet benefits to be paid to plan participants. During the six months ended June 30, 2005, the Company contributed \$9,422 to the plans. The Company anticipates contributing an additional \$9,422 to the plans in 2005.

The following table aggregates the components of the plans' net periodic pension cost for the six months ended June 30, 2005:

Service cost	\$ 179 <b>,</b> 999
Interest cost	252,165
Expected return on plan assets	(394,669)
${\tt Amortization\ of\ prior\ service\ cost}$	63 <b>,</b> 277
Amortization of net loss	94,231
Net periodic pension cost	\$ 195,003

The Company also sponsors a defined contribution plan that covers substantially all employees. For the six months ended June 30, 2005, the Company expensed contributions of \$88,304. The Company does not provide postretirement medical benefits.

### 6. Stock-Based Compensation

The Stock Option Plan adopted in 1985 ("1985 Plan") permits the issuance of stock options and stock appreciation rights for the purchase of up to 2,610,146 shares of the Company's Common Stock at the fair market value on the date of grant. The exercise price of the options and related stock appreciation rights is reduced by the per share amount of capital gains paid by the Company during subsequent years. Options are exercisable beginning not less than one year after the date of grant and stock appreciation rights are exercisable beginning not less than two years after the date of grant. The stock appreciation rights allow the holders to surrender their rights to exercise their options and receive cash in an amount equal to the difference between the option exercise price and the fair market value of the Common Stock at the date of surrender. All options terminate 10 years from the date of grant if not exercised. With the adoption of the 2005 Equity Incentive Compensation Plan ("2005 Plan") at the 2005 Annual Meeting, no further grants will be made under the 1985 Plan, although unexercised awards granted in 2004 and prior years remain outstanding.

A summary of option activity under the 1985 Plan as of June 30, 2005, and changes during the period then ended is presented below:

	Options	Weighted- Average Exercise Price	Weighted- Average Remaining Life (Years)
-			
Outstanding at January 1, 200 Exercised Forfeited	05 283 <b>,</b> 297  	\$11.76  	
Outstanding at June 30, 2005	283,297	\$11.75	5.97
Exercisable at June 30, 2005	180 <b>,</b> 888	\$11.44	5.86

The options outstanding as of June 30, 2005 are set forth below:

Exercise Price	Options Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Life (Years)
\$3.00-\$6.74 \$6.75-\$10.49 \$10.50-\$14.24 \$14.25-\$18.00	23,418 72,764 135,967 51,148	\$ 4.18 9.67 10.85 17.59	1.15 6.44 6.88 5.09
Outstanding at June 30, 2005	283,297		

Compensation cost resulting from stock options and stock appreciation rights granted under the 1985 Plan is based on the intrinsic value of the award, recognized over the award's vesting period, and remeasured at each reporting date through the date of settlement. The total compensation cost recognized for the six months ended June 30, 2005 was (\$8,205).

The 2005 Plan permits the grant of stock options, restricted stock awards and other stock incentives to key employees and all non-employee directors. The 2005 Plan provides for the issuance of up to 3,413,131 shares of the Company's Common Stock. Restricted stock was granted to key employees on April 27, 2005 at fair market value on that date, vesting over a three year period. Restricted stock units were granted to non-employee directors on April 27, 2005 at fair market value on that date and vest over a one year period. The number of shares of Common Stock which remain available for future grants under the Plan at June 30, 2005 is 3,392,440 shares. The Company pays dividends and dividend equivalents on outstanding awards, which are charged to net assets when paid. Dividends and dividend equivalents paid on restricted awards that are later forfeited are reclassified to compensation expense.

A summary of the status of the Company's awards granted as of June 30, 2005, and changes during the period then ended is presented below:

Awards	Shares/Units	Grant-Date Fair Value
Balance at January 1, 2005 Granted:		
Restricted stock	13,941	\$12.56
Restricted stock units	6 <b>,</b> 750	12.56
Vested		
Forfeited		
Nonvested at June 30, 2005	20,691	\$12.56

Compensation costs resulting from restricted stock and restricted stock units granted under the 2005 Plan are recognized over the relevant service period

based on the fair value of the awards granted. Any unearned compensation is included in "Undistributed net investment income" and is subsequently expensed as services are rendered. The fair value of restricted stock is based on the average of the high and low market price on the date an award is granted. The total compensation costs for restricted stock granted to employees for the six months ended June 30, 2005 was \$9,728. The total compensation costs for restricted stock units granted to non-employee directors

6

### NOTES TO FINANCIAL STATEMENTS (CONTINUED)

\_\_\_\_\_\_

under the 2005 Plan for the six months ended June 30, 2005 was \$14,130. As of June 30, 2005, there was \$236,021 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the 2005 Plan. That cost is expected to be recognized over a weighted average period of 2.2 years.

### 7. Expenses

The aggregate remuneration paid or accrued during the six months ended June 30, 2005 to officers and directors amounted to \$1,518,593, of which \$147,463 was paid or accrued as fees to directors who were not officers.

#### 8. Portfolio Securities Loaned

The Company makes loans of securities to brokers, secured by cash deposits, U.S. Government securities, or bank letters of credit. The Company accounts for securities lending transactions as secured financing and receives compensation in the form of fees or retains a portion of interest on the investment of any cash received as collateral. The Company also continues to receive interest or dividends on the securities loaned. The loans are secured at all times by collateral of at least 102% of the fair value of the securities loaned plus accrued interest. Gain or loss in the fair value of the securities loaned that may occur during the term of the loan will be for the account of the Company. At June 30, 2005, the Company had no securities on loan.

7

### FINANCIAL HIGHLIGHTS

\_\_\_\_\_\_

Six Months Ended

 June 30,
 June 30,
 Year Ended December

 2005
 2004
 2004
 2003
 2002

Per Share Operating Performance Net asset value, beginning of period \$15.04 \$14.36 \$14.36 \$12.12 \$16.05 Net investment income 0.10 0.09 0.23\* 0.19 0.20 Net realized gains and increase(decrease) in (0.01) 0.43 1.39 2.85 (3.38) unrealized appreciation 0.09 0.52 1.62 3.04 (3.18) Total from investment operations Less distributions Dividends from net investment  $(0.09) \qquad (0.08) \qquad (0.24) \qquad (0.17) \qquad (0.19)$ Distributions from net  $(0.01) \qquad (0.02) \qquad (0.66) \qquad (0.61) \qquad (0.57)$ realized gains (0.10) (0.10)(0.90)(0.78) (0.76)Total distributions 0.01 0.03 0.02 0.04 Capital share repurchases 0.05 Reinvestment of distributions (0.06)(0.06) (0.04) 0.03 0.01 (0.04) (0.02) 0.01 Total capital share transactions Net asset value, end of period \$15.06 \$14.79 \$15.04 \$14.36 \$12.12 \_\_\_\_\_ Per share market price, end \$12.87 \$12.72 \$13.12 \$12.41 \$10.57 of period Total Investment Return Based on market price (1.2)% 3.3% 13.2% 25.2% (20.6)% 3.8% 26.3% (19.4)% 0.9% 12.1% Based on net asset value Ratios/Supplemental Data Net assets, end of period (in 000's) \$1,279,265 \$1,248,430 \$1,295,549 \$1,218,862 \$1,024,810 \$ Ratio of expenses to average 0.44%+ 0.43%+ 0.43% 0.47% 0.34% net assets Ratio of net investment income to

average net assets

Number of shares outstanding at

Portfolio turnover

1.37%+ 1.25%+ 1.54% 1.45% 1.42%

14.82%+ 13.10%+ 13.43% 12.74% 17.93%

end of period (in 000's) 84,961 84,409 86,135 84,886 84,536

-----

8

### SCHEDULE OF INVESTMENTS

\_\_\_\_\_

June 30, 2005

	Shares	Value (A)
_		
Stocks and Convertible Securities - Consumer 17.0% Consumer Discretionary 6.4%	- 97.2%	
Brinker International Inc. (B) Clear Channel Communications	190,000	\$ 7,609,500
Inc.	350,000	10,825,500
Comcast Corp. (B) Gannett Co., Inc.	325,000 87,500	9,977,500 6,223,875
Newell Rubbermaid Inc. Outback Steakhouse, Inc.	515,000 225,000	12,277,600 10,179,000
Target Corp.	460,000	25,028,600
		82,121,575
Consumer Staples 10.6% BJ's Wholesale Club, Inc. (B) Bunge Ltd. Coca-Cola Co.	500,000 205,000 200,000	16,245,000 12,997,000 8,350,000
Dean Foods Co. (B)	500,000	17,620,000
Del Monte Foods Co. (B) PepsiCo, Inc.	1,115,000 440,000	12,008,550 23,729,200
Procter & Gamble Co. Safeway, Inc.	340,000 423,000	17,935,000 9,555,570
Treehouse Foods Inc. (B) Unilever plc ADR	100,000 345,000	2,851,000 13,403,250
		134,694,570
Energy 10.3%		
BP plc ADR ConocoPhillips	270,000 380,000	16,842,600 21,846,200
Exxon Mobil Corp.	130,000	7,471,100
Murphy Oil Corp. Petroleum & Resources	229,600	11,992,008
Corporation (C) Schlumberger Ltd.	1,985,996 190,000	
schrumberger bla.	190,000	14,428,600
		132,160,388

<sup>\*</sup> In 2004 the Fund received \$2,400,000, or \$0.03 per share, in an extraordinary dividend from Microsoft Corp.

<sup>+</sup> Ratios presented on an annualized basis.

Financials 15.6%		
Banking 11.5%		
Bank of America Corp.	550,000	25,085,500
BankAtlantic Bancorp Inc.	300,000	5,685,000
Compass Bancshares Inc.	300,000	13,500,000
Fifth Third Bancorp	270,000	11,126,700
	270,000	11,120,700
Investors Financial Services		
Corp.	380,000	14,371,600
North Fork Bancorporation, Inc.	450,000	12,640,500
		6,382,000
Provident Bankshares Corp.	200,000	
Wachovia Corp.	370,000	18,352,000
Wells Fargo & Co.	400,000	24,632,000
Wilmington Trust Corp.	420,000	15,124,200
1	•	
		146 000 500
		146,899,500
Insurance 4.1%		
AMBAC Financial Group, Inc.	295,000	20,579,200
- ·	233,000	20,073,200
American International Group,		
Inc.	550,000	31,955,000
		52,534,200
		02,001,200
	Shares	Value (A)
_		
Health Care 13.2%		
Health Care 13.2%	350 000 9	\$ 17 153 500
Abbott Laboratories		\$ 17,153,500
Abbott Laboratories Bristol-Myers Squibb Co.	345,000	8,618,100
Abbott Laboratories		
Abbott Laboratories Bristol-Myers Squibb Co.	345,000 250,000	8,618,100 20,070,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc.	345,000 250,000 325,000	8,618,100 20,070,000 18,417,750
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson	345,000 250,000	8,618,100 20,070,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America	345,000 250,000 325,000 255,000	8,618,100 20,070,000 18,417,750 16,575,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson	345,000 250,000 325,000	8,618,100 20,070,000 18,417,750
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America	345,000 250,000 325,000 255,000	8,618,100 20,070,000 18,417,750 16,575,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B)	345,000 250,000 325,000 255,000 235,000 225,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 325,000 125,000 67,000 300,000 300,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250  169,501,100 3,862,550 11,580,000 10,353,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 325,000 125,000 67,000 300,000 300,000	8,618,100 20,070,000 18,417,750 16,575,000 11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250  169,501,100 3,862,550 11,580,000 10,353,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 325,000 125,000 125,000 67,000 300,000 300,000 200,000 1,487,700	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 125,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000 160,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000 11,568,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co. United Parcel Service, Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 125,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co. United Parcel Service, Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000 160,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000 11,568,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000 160,000 155,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000 11,568,000 10,719,800
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co. United Parcel Service, Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000 160,000 155,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250  169,501,100  3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000 11,568,000 10,719,800 15,405,000
Abbott Laboratories Bristol-Myers Squibb Co. Genentech, Inc. (B) HCA Inc. Johnson & Johnson Laboratory Corp. of America Holdings (B) MedImmune, Inc. (B) Medtronic Inc. Pfizer Inc. Wyeth Co. Zimmer Holdings Inc. (B)  Industrials 10.7% Canadian National Railway Co. Cintas Corp. Donnelley (R.R.) & Sons Co. Emerson Electric Co. General Electric Co. Illinois Tool Works Inc. 3M Co. United Parcel Service, Inc.	345,000 250,000 325,000 255,000 235,000 225,000 310,000 1,120,000 325,000 125,000 67,000 300,000 300,000 200,000 1,487,700 125,000 160,000 155,000	8,618,100 20,070,000 18,417,750 16,575,000  11,726,500 6,012,000 16,054,900 30,889,600 14,462,500 9,521,250 169,501,100 3,862,550 11,580,000 10,353,000 12,526,000 51,548,805 9,960,000 11,568,000 10,719,800

Information Technology -- 13.9%

Communication Equipment 2.	3%	
Avaya Inc. (B)	600,000	4,992,000
Corning Inc. (B)	1,000,000	16,620,000
Lucent Technologies Inc. (B)	2,900,000	8,439,000
		30,051,000
Computer Related 9.4%		
Automatic Data Processing		
Inc.	300,000	12,591,000
BEA Systems Inc. (B)	800,000	7,024,000
Cisco Systems, Inc. (B)	1,200,000	22,932,000
Dell Inc. (B)	400,000	15,804,000
DiamondCluster		
International Inc. (B)	497,500	5,621,750
Microsoft Corp.	800,000	19,872,000
Oracle Corp. (B)	880,000	11,616,000
Sapient Corp. (B)	1,150,000	9,119,500
Siebel Systems Inc.	800,000	7,120,000
Sun Microsystems Inc. (B)	95,000	354 <b>,</b> 350
Symantec Corp. (B)	400,000	8,696,000
		120,750,600
Electronics 2.2%		
Cree, Inc. (B)	500,000	12,735,000
Intel Corp.	310,000	8,078,600
Solectron Corp. (B)	1,850,000	7,011,500
		27,825,100

9

# SCHEDULE OF INVESTMENTS (CONTINUED)

\_\_\_\_\_\_

June 30, 2005

	Shares	Value (A)
Materials 5.3% Air Products and Chemicals, Inc.	250,000	\$ 15,075,000
du Pont (E.I.) de Nemours and	400,000	17,204,000
Martin Marietta Materials, Inc.	141,600	9,787,392
Rohm & Haas Co. Smurfit-Stone Container	400,000	18,536,000
Corp. (B)	650,000	6,610,500
		67,212,892
Telecom Services 4.2%		
Alltel Corp.	350,000	21,798,000

BellSouth Corp.  SBC Communications I:  Vodafone Group plc	200,000 nc. 595,000	5,314,000 14,131,250
ADS	492,613	11,980,348
		53,223,598
Utilities 7.0%		
Aqua America, Inc.	900,000	26,766,000
Black Hills Corp.	245,000	9,028,250
CINergy Corp.	300,000	13,446,000
Duke Energy Corp.	611,560	18,181,679
Keyspan Corp.	140,000	5,698,000
MDU Resources Group,	Inc. 575,000	16,197,750
		89,317,679
Total Stocks and Conver	tible Securities	
(Cost \$918,653,740) (D		\$1,243,815,357

	Prin. Amt.	Value (A)
Short-Term Investments 2.4% U.S. Government Obligations 1.4% U.S. Treasury Bills, 2.77%, due 8/18/05	\$17,500,000	\$ 17,434,666
Time Deposit 0.0% Citibank N.A., 2.70%, due 7/1/05		101,346
Commercial Paper 1.0% AIG Funding Inc., 3.21%, due 7/12/05 General Electric Capital Corp.,	1,275,000	1,273,749
2.99-3.25%, due 7/7/05-7/19/05 Toyota Motor Credit Corp., 3.19-3.24%,	5,500,000	5,493,316
due 7/14/05-7/21/05	6,475,000	6,464,707
		13,231,772
Total Short-Term Investments (Cost \$30,767,784)		30,767,784
Total Investments 99.6% (Cost \$949,421,524) Cash, receivables and other		1,274,583,141
assets, less liabilities 0.4%		4,681,951
Net Assets 100%		\$1,279,265,092 =======

Notes:

<sup>(</sup>A) See note 1 to financial statements. Securities are listed on the New York

Stock Exchange, the American Stock Exchange or the NASDAQ.

- (B) Presently non-dividend paying.
- (C) Non-controlled affiliate, a closed-end sector fund, registered as an investment company under the Investment Company Act of 1940.
- (D) The aggregate market value of stocks held in escrow at June 30, 2005 covering open call option contracts written was \$23,284,850. In addition, the aggregate market value of securities segregated by the Company's custodian required to collateralize open put option contracts written was \$12,912,500.

10

### PORTFOLIO SUMMARY

\_\_\_\_\_\_

Ten Largest Portfolio Holdings (6/30/05)

	Market Value %	of Net Assets
Petroleum & Resources Corporation*	\$ 59,579,880	4.7
General Electric Co.	51,548,805	4.0
American International Group, Inc.	31,955,000	2.5
Pfizer Inc.	30,889,600	2.4
Aqua America, Inc.	26,766,000	2.1
Bank of America Corp.	25,085,500	2.0
Target Corp.	25,028,600	2.0
Wells Fargo & Co.	24,632,000	1.9
PepsiCo, Inc.	23,729,200	1.8
Cisco Systems, Inc.	22,932,000	1.8
Total	\$322,146,585	25.2%

\*Non-controlled affiliate Sector Weightings (6/30/05)

	[CHART]
Consumer	17.0
Energy	10.3
Financial	15.6
Health Care	13.2
Industrials	10.7
Information Technology	13.9
Materials	5.3
Telecom Services	4.2
Utilities	7.0
Cash & Equivalent	2.4

11

SCHEDULE OF OUTSTANDING OPTION CONTRACTS

June 30, 2005

Contracts (100 shares each)	Security	Strike Price	Cont: Expi: Date	ration	Appreciation/ (Depreciation)
200	COVERED CALLS Air Products & Chemicals, Inc.	\$ 65	Sep	05	\$ 5,399
100	AMBAC Financial Group, Inc.	75	Jul	05	11,699
100	AMBAC Financial Group, Inc.	75	Aug	0.5	7,199
100	AMBAC Financial Group, Inc.	85	Aug	0.5	10,699
100	AMBAC Financial Group, Inc.	90	Aug	05	12,544
100	AMBAC Financial Group, Inc.	85	Nov	05	18,574
500	American International Group, Inc.	60	Aug	05	20,997
150	Brinker International, Inc.	40	Jul	05	7,049
100	Brinker International, Inc.	40	Oct	05	(6,801)
30	Canadian National Railway Co.	65	Jul	05	2,210
200	ConocoPhillips	65	Aug	05	1,750
150	HCA Inc.	47.50	Aug	05	(127,201)
250	HCA Inc.	50	Aug	05	(150,626)
100	HCA Inc.	60	Aug	05	4,200
100	Illinois Tool Works Inc.	105	Sep	0.5	(40,300)
100	Illinois Tool Works Inc.	90	Dec	05	(5,301)
100	Investors Financial Services Corp.	55	Jul	05	14,850
100	Investors Financial Services Corp.	60	Jul	05	10,700
150	Laboratory Corp. of America Holdings	55	Aug	05	11,549
200 200	Martin Marietta Materials, Inc.	70 50	Oct Jul	05 05	(33,601)
200	Murphy Oil Corp. Murphy Oil Corp.	60	Oct	05	(46,300) (12,300)
150	Target Corp.	60	Oct	05	(4,800)
100	Target Corp.	60	Jan	06	5 <b>,</b> 399
100	3M Co.	90	Jul	05	9 <b>,</b> 200
200	United Technologies Corp.	55	Jul	05	10,699
200	United Technologies Corp.	55	Aug	0.5	7,950
200	United Technologies Corp.	57.50	Aug	05	7,470
4,280					(247,093)
	COLLATERALIZED PUT	S			
250	Automatic Data Processing Inc.	40	Aug	05	14,249
100	Bank of America Corp.	45	Aug	05	8,199
250	Bunge Ltd.	45	Jul	05	16,749
150	Bunge Ltd.	50	Jul	05	23,549
150	Cintas Corp.	35	Nov	0.5	6,299
100	Exxon Mobil Corp.	55	Jul	0.5	6,200
100	Exxon Mobil Corp.	50	Oct	05	6,699
250	Fifth Third Bancorp	40	Aug	05	14,249
100	Fifth Third Bancorp	40	Nov	05	(2,801)
100	Gannett Co., Inc.	75 70	Jul	05	(26,300)
150	Gannett Co., Inc. Investors Financial Services Corp.	37.50	Oct	05 05	(16,201) (13,951)
150 200	Martin Marietta Materials, Inc.	45	Oct Jul	05	16,772
10	Martin Marietta Materials, Inc.	50	Jul	05	970
200	Murphy Oil Co.	35	Jul	05	10,417
100	3M Co.	65	Oct	05	2,200
100	United Parcel Service, Inc.	70	Jul	05	(2,300)
100	United Parcel Service, Inc.	60	Oct	05	2,700

						\$(181,694)
2,660						65 <b>,</b> 399
100	United Parcel Service,	Inc.	65	Oct	05	(2,300)

12

### CHANGES IN PORTFOLIO SECURITIES

\_\_\_\_\_

# During the Three Months Ended June 30, 2005 (unaudited)

		Shares	
	Additions	Reductions	Held June 30, 2005
Automatic Data Processing Inc  Bank of America Corp.  Bank Atlantic Bancorp Inc  Bunge Ltd  Clear Channel Communications Inc  ConocoPhillips  Del Monte Foods Co  Fifth Third Bancorp.  Murphy Oil Corp  Outback Steakhouse, Inc  Treehouse Foods Inc  United Parcel Service, Inc  United Technologies Corp.  AMBAC Financial Group, Inc  Brinker International Inc  Canadian National Railway Co  Corning Inc  Dean Foods Co  Enzon Pharmaceuticals, Inc  HCA Inc  Johnson & Johnson.  Laboratory Corp. of America Holdings	Additions 75,000 50,000 80,000 35,000 25,000 190,000/(1)/ 80,000 70,000 144,800/(1)/ 225,000 100,000/(2)/ 10,000 150,000/(1)/		
Provident Bankshares Corp  Ryland Group Inc  Sun Microsystems Inc		135,021 20,000 315,000	200,000  95,000

<sup>/(1)/</sup> By Stock Split.

-----

This report, including the financial statements herein, is transmitted to the stockholders of The Adams Express Company for their information. It is not a

 $<sup>/\</sup>left(2\right)/$  Received 1 share of Treehouse Foods Inc. for 5 shares of Dean Foods Co. held.

prospectus, circular or representation intended for use in the purchase or sale of shares of the Company or of any securities mentioned in the report. The rates of return will vary and the principal value of an investment will fluctuate. Shares, if sold, may be worth more or less than their original cost. Past performance is not indicative of future investment results.

13

#### HISTORICAL FINANCIAL STATISTICS

\_\_\_\_\_\_

				Dividends	Distributions
			Net	from	from
			Asset	Net Investment	Net Realized
	Value of	Shares	Value per	Income	Gains
December 31	Net Assets	Outstanding*	Share*	per Share*	per Share*
1995	\$ 986,230,914	69,248,276	\$14.24	\$.35	\$ .76
1996	1,138,760,396	72 <b>,</b> 054 <b>,</b> 792	15.80	.35	.80
1997	1,424,170,425	74 <b>,</b> 923 <b>,</b> 859	19.01	.29	1.01
1998	1,688,080,336	77,814,977	21.69	.30	1.10
1999	2,170,801,875	80,842,241	26.85	.26	1.37
2000	1,951,562,978	82,292,262	23.72	.22	1.63
2001	1,368,366,316	85,233,262	16.05	.26	1.39
2002	1,024,810,092	84,536,250	12.12	.19	.57
2003	1,218,862,456	84,886,412	14.36	.17	.61
2004	1,295,548,900	86,135,292	15.04	.24	.66
June 30, 2005	1,279,265,092	84,960,583	15.06	.14+	.01+

\_\_\_\_\_

14

### REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

\_\_\_\_\_\_

To the Board of Directors and Stockholders of The Adams Express Company:

In our opinion, the accompanying statement of assets and liabilities, including the schedule of investments, and the related statements of operations and of changes in net assets and the financial highlights present fairly, in all material respects, the financial position of The Adams Express Company (hereafter referred to as the "Company") at June 30, 2005, and the results of its operations, the changes in its net assets and the financial highlights for each of the fiscal periods presented, in conformity with accounting principles

<sup>\*</sup> Prior years have been adjusted to reflect the 3-for-2 stock split effected in October 2000.

<sup>+</sup> Paid or declared.

generally accepted in the United States of America. These financial statements and financial highlights (hereafter referred to as "financial statements") are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits, which included confirmation of securities at June 30, 2005, by correspondence with the custodian and brokers, provide a reasonable basis for our opinion.

PricewaterhouseCoopers LLP Baltimore, Maryland July 13, 2005

15

### OTHER INFORMATION

\_\_\_\_\_\_

Statement on Quarterly Filing of Complete Portfolio Schedule

In addition to publishing its complete schedule of portfolio holdings in the First and Third Quarter Reports to shareholders, the Company files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Company's Forms N-Q are available on the Commission's website at www.sec.gov. The Company's Forms N-Q may be reviewed and copied at the Commission's Public Reference Room, and information on the operation of the Public Reference Room may be obtained by calling 1-800-SEC-0330. The Company also posts its Forms N-Q on its website at www.adamsexpress.com under the heading "Financial Reports".

Proxy Voting Policies and Record

A description of the policies and procedures that the Company uses to determine how to vote proxies relating to portfolio securities owned by the Company and information as to how the Company voted proxies relating to portfolio securities during the 12 month period ended June 30, 2005 are available (i) without charge, upon request, by calling the Company's toll free number at (800) 638-2479; (ii) on the Company's website by clicking on "Corporate Information" heading on the website; and (iii) on the Securities and Exchange Commission's website at http://www.sec.gov.

Privacy Policy

In order to conduct its business, The Adams Express Company collects and maintains certain nonpublic personal information about our stockholders of record with respect to their transactions in shares of our securities. This information includes the stockholder's address, tax identification or Social Security number, share balances, and dividend elections. We do not collect or maintain personal information about stockholders whose shares of our securities are held in "street name" by a financial institution such as a bank or broker.

We do not disclose any nonpublic personal information about you, our other stockholders or our former stockholders to third parties unless necessary to process a transaction, service an account or as otherwise permitted by law.

To protect your personal information internally, we restrict access to nonpublic personal information about our stockholders to those employees who need to know that information to provide services to our stockholders. We also maintain certain other safeguards to protect your nonpublic personal information.

\_\_\_\_\_

Common Stock
Listed on the New York Stock Exchange
and the Pacific Exchange

The Adams Express Company
Seven St. Paul Street, Suite 1140, Baltimore, MD 21202
(410) 752-5900 or (800) 638-2479
Website: www.adamsexpress.com
E-mail: contact@adamsexpress.com

Counsel: Chadbourne & Parke L.L.P.

Independent Registered Public Accounting Firm: PricewaterhouseCoopers LLP
 Transfer Agent & Registrar: American Stock Transfer & Trust Co.
 Custodian of Securities: Brown Brothers Harriman & Co.

16

### ANNUAL MEETING OF STOCKHOLDERS

\_\_\_\_\_\_

The Annual Meeting of Stockholders was held on April 27, 2005. For those nominated, the following votes were cast for directors:

_		votes for	votes withheld
(A)	Enrique R. Arzac:	71,167,716	1,391,281
(B)	Phyllis O. Bonanno:	70,885,091	1,673,906
(C)	Daniel E. Emerson:	70,654,340	1,904,657
(D)	Thomas H. Lenagh:	70,394,630	2,164,367
(E)	W.D. MacCallan:	70,805,684	1,753,313
(F)	Kathleen T. McGahran:	71,041,299	1,517,698
(G)	Douglas G. Ober:	71,093,555	1,465,442
(H)	John J. Roberts:	70,676,777	1,882,220
(I)	Susan C. Schwab:	71,042,734	1,516,263

(J) Robert J.M. Wilson: 70,650,502 1,908,495

A proposal to approve and ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for 2005 was approved with 71,392,716 votes for, 617,879 votes against, and 548,402 shares abstaining.

A proposal to approve The Adams Express Company 2005 Equity Incentive Compensation Plan was approved with 36,347,317 votes for, 7,978,412 votes against, 2,199,191 shares abstaining, and 26,034,078 shares unvoted.

17

#### SHAREHOLDER INFORMATION AND SERVICES

\_\_\_\_\_\_

#### DIVIDEND PAYMENT SCHEDULE

The Corporation presently pays dividends four times a year, as follows: (a) three interim distributions on or about March 1, June 1, and September 1 and (b) a "year-end" distribution, payable in late December, consisting of the estimated balance of the net investment income for the year and the net realized capital gain earned through October 31. Stockholders may elect to receive the year-end distribution in stock or cash. In connection with this distribution, all stockholders of record are sent a dividend announcement notice and an election card in mid-November.

Stockholders holding shares in "street" or brokerage accounts may make their election by notifying their brokerage house representative.

#### INVESTORS CHOICE

INVESTORS CHOICE is a direct stock purchase and sale plan, as well as a dividend reinvestment plan, sponsored and administered by our transfer agent, American Stock Transfer & Trust Company (AST). The plan provides registered stockholders and interested first time investors an affordable alternative for buying, selling, and reinvesting in Adams Express shares.

The costs to participants in administrative service fees and brokerage commissions for each type of transaction are listed below.

Initial Enrollment and Optional Cash Investments

Service Fee \$2.50 per investment Brokerage Commission \$0.05 per share

Reinvestment of Dividends\*

Service Fee 2% of amount invested (maximum of \$2.50 per investment)

Brokerage Commission \$0.05 per share

Sale of Shares

Service Fee \$10.00 Brokerage Commission \$0.05 per share

Deposit of Certificates for safekeeping \$7.50..

Book to Book Transfers

Included

To transfer shares to another participant or to a new participant

Fees are subject to change at any time. Minimum and Maximum Cash Investments

Initial minimum investment (non-holders) \$500.00

Minimum optional investment
 (existing holders) \$50.00

Electronic Funds Transfer
 (monthly minimum) \$50.00

Maximum per transaction \$25,000.00

Maximum per year NONE

A brochure which further details the benefits and features of INVESTORS CHOICE as well as an enrollment form may be obtained by contacting AST.

For Non-Registered Shareholders

For shareholders whose stock is held by a broker in "street" name, the AST INVESTORS CHOICE Direct Stock Purchase and Sale Plan remains available through many registered investment security dealers. If your shares are currently held in a "street" name or brokerage account, please contact your broker for details about how you can participate in AST's Plan or contact AST.

-----

The Company
The Adams Express Company
Lawrence L. Hooper, Jr.
Vice President, General Counsel and Secretary
Seven St. Paul Street, Suite 1140, Baltimore, MD 21202
(800) 638-2479
Website: www.adamsexpress.com
E-mail: contact@adamsexpress.com

The Transfer Agent
American Stock Transfer & Trust Company
Address Shareholder Inquiries to:

Shareholder Relations Department
59 Maiden Lane

New York, NY 10038 (877) 260-8188

Website: www.amstock.com E-mail: info@amstock.com

Investors Choice Mailing Address:
Attention: Dividend Reinvestment
 P.O. Box 922
Wall Street Station
New York, NY 10269

Website: www.InvestPower.com E-mail: info@InvestPower.com

\*The year-end dividend and capital gain distribution will usually be made in newly issued shares of common stock. There are no fees or commissions in connection with this dividend and capital gain distribution when made in newly issued shares.

- Item 2: Code(s) of Ethics for senior financial officers Item not applicable to semi-annual report.
- Item 3: Audit Committee Financial Expert Item not
  applicable to semi-annual report.
- Item 4: Principal Accountant Fees and Services Item not
  applicable to semi-annual report.
- Item 5: Audit Committee of Listed Registrants Item not
  applicable to semi-annual report.
- Item 6: Schedule of Investments This schedule is included as part of the report to shareholders filed under Item 1 of this form.
- Item 7: Disclosure of Proxy Voting Policies and Procedures
  for Closed-End Management Investment Companies Item not
  applicable to semi-annual report.
- Item 8: Portfolio Managers of Closed-End Management
  Investment Companies Item not applicable to semi-annual
  report.

Item 9: Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.

Period(2)	Units)	Average Price Paid per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
Jan. 2005 Feb. 2005 Mar. 2005 Apr. 2005 May 2005 June 2005	330,800 266,100 195,800 14,300 156,700 231,700	\$ 12.91 \$ 13.04 \$ 12.93 \$ 12.79 \$ 12.81 \$ 13.05	330,800 266,100 195,800 14,300 156,700 231,700	3,782,453 3,516,353 3,320,553 3,306,253 3,149,553 2,917,853
Total	1,195,400(1)	\$ 12.96	1,195,400(2)	2,917,853(2)

<sup>(1)</sup> There were no shares purchased other than through a publicly announced plan or program.

<sup>(2.</sup>a) The Plan was announced on December 9, 2004.

<sup>(2.</sup>b) The share amount approved was 5% of outstanding shares, or approximately 4,172,453 shares.

<sup>(2.</sup>c) The Plan will expire on or about December 8, 2005.

<sup>(2.</sup>d) None.

<sup>(2.</sup>e) None.

Item 10: Submission of Matters to a Vote of Security Holders - There were no material changes to the procedures by which shareholders may recommend nominees to the registrant's board of directors made or implemented after the registrant last provided disclosure in response to the requirements of Item 7(d)(2)(ii)(G) of Schedule 14A (17 CFR 240.14a-101), or this Item.

Item 11: Controls and Procedures.

- (a) The registrant's Principal Executive Officer and Principal Financial Officer have evaluated the registrant's disclosure controls and procedures within 90 days of this filing and have concluded that the registrant's disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.
- (b) Internal Controls. Effective April 25, 2005, the Company changed custodian from The Bank of New York to Brown Brothers Harriman & Co. There were no significant changes in the registrant's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Item 12: Exhibits attached hereto. (Attach certifications
as exhibits)

- (1) Not required at this time.
- (2) Separate certifications by the registrant's principal executive officer and principal financial officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2 under the Investment Company Act of 1940, are attached.
- A certification by the registrant's principal executive officer and principal financial officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is attached.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THE ADAMS EXPRESS COMPANY

BY: /s/ Douglas G. Ober

-----

Douglas G. Ober Chief Executive Officer (Principal Executive Officer)

Date: July 28, 2005

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates

indicated.

BY: /s/ Douglas G. Ober

\_\_\_\_\_

Douglas G. Ober

Chief Executive Officer (Principal Executive Officer)

Date: July 28, 2005

BY: /s/ Maureen A. Jones

\_\_\_\_\_\_

Maureen A. Jones

Vice President, Chief Financial Officer and Treasurer

(Principal Financial Officer)

Date: July 28, 2005